Lynparza (olaparib) — United Healthcare

Initial criteria

• Diagnosis of pancreatic adenocarcinoma
• Disease is metastatic
• Presence of deleterious or suspected deleterious germline BRCA1/2 mutation
• Disease has not progressed while receiving at least 16 weeks of a first-line platinum-based chemotherapy regimen

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lynparza therapy

Approval duration

12 months